Endovascular treatment for basilar artery occlusion: a meta-analysis

Two previously published randomised control studies (RCTs), BEST (Basilar Artery Occlusion Endovascular Intervention versus Standard Medical Treatment) and BASICS (Basilar Artery International Cooperation Study), failed to achieve an advantage of EVT over standard medical treatment (SMT) .10 11 Rece...

Full description

Saved in:
Bibliographic Details
Published in:Stroke and vascular neurology 2023-02, Vol.8 (1), p.1-3
Main Authors: Xu, Jiawen, Chen, Xi, Chen, Shidong, Cao, Wenjie, Zhao, Hongchen, Ni, Wei, Zhang, Yanrong, Gao, Chao, Gu, Yuxiang, Cheng, Xin, Dong, Yi, Dong, Qiang
Format: Article
Language:English
Subjects:
Arterial Occlusive Diseases
Basilar Artery
Bias
Clinical outcomes
Clinical trials
Editorial
Enrollments
Flow velocity
Hemorrhage
Humans
Medical treatment
Meta-analysis
Minority & ethnic groups
Mortality
Stroke
Stroke - therapy
Thrombectomy
Thrombolytic Therapy
Veins & arteries
Vertebrobasilar Insufficiency - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two previously published randomised control studies (RCTs), BEST (Basilar Artery Occlusion Endovascular Intervention versus Standard Medical Treatment) and BASICS (Basilar Artery International Cooperation Study), failed to achieve an advantage of EVT over standard medical treatment (SMT) .10 11 Recently, two other RCTs from China, ATTENTION (Endovascular Treatment For Acute Basilar Artery Occlusion: A Multicentre Randomised Clinical Trial) and BAOCHE (Basilar Artery Occlusion Chinese Endovascular), were presented at the European Stroke Organisation Conference 2022.12 13 The ATTENTION trial showed that EVT was associated with the better functional outcomes at 90 days, achieving a higher rate of modified Rankin Scale (mRS) score of ≤3 (46.0% vs 22.8%; adjusted relative risk (aRR) 2.1, 95% CI 1.5 to 3.0, p
ISSN:2059-8688
2059-8696
DOI:10.1136/svn-2022-001740